Vaccination Route as a Determinant of Protective Antibody Responses against Herpes Simplex Virus.

Vaccines
Clare Burn AschnerBetsy C Herold

Abstract

Herpes simplex viruses (HSV) are significant global health problems associated with mucosal and neurologic disease. Prior experimental vaccines primarily elicited neutralizing antibodies targeting glycoprotein D (gD), but those that advanced to clinical efficacy trials have failed. Preclinical studies with an HSV-2 strain deleted in gD (ΔgD-2) administered subcutaneously demonstrated that it elicited a high titer, weakly neutralizing antibodies that activated Fcg receptors to mediate antibody-dependent cellular cytotoxicity (ADCC), and completely protected mice against lethal disease and latency following vaginal or skin challenge with HSV-1 or HSV-2. Vaccine efficacy, however, may be impacted by dose and route of immunization. Thus, the current studies were designed to compare immunogenicity and efficacy following different routes of vaccination with escalating doses of ΔgD-2. We compared ΔgD-2 with two other candidates: recombinant gD protein combined with aluminum hydroxide and monophosphoryl lipid A adjuvants and a replication-defective virus deleted in two proteins involved in viral replication, dl5-29. Compared to the subcutaneous route, intramuscular and/or intradermal immunization resulted in increased total HSV antibod...Continue Reading

References

Mar 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J P BryanL J Legters
Jan 1, 1987·Scandinavian Journal of Infectious Diseases·M Wahl, S Hermodsson
Jun 9, 1999·Proceedings of the National Academy of Sciences of the United States of America·X J Da CostaD M Knipe
Aug 17, 1999·Journal of Leukocyte Biology·B DuboisF Brière
Feb 3, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·F RahmanH F Löhr
Apr 14, 2000·The Journal of Infectious Diseases·W E LaffertyA Wald
Apr 18, 2002·Proceedings of the National Academy of Sciences of the United States of America·Stanford L PengLaurie H Glimcher
Nov 22, 2002·The New England Journal of Medicine·Lawrence R StanberryUNKNOWN GlaxoSmithKline Herpes Vaccine Efficacy Study Group
Nov 5, 2004·The New England Journal of Medicine·Robert B BelsheGary Dubin
Aug 24, 2006·JAMA : the Journal of the American Medical Association·Fujie XuLauri E Markowitz
Dec 25, 2007·Lancet·Rachna GuptaAnna Wald
Oct 17, 2008·Nature Reviews. Microbiology·Quentin Sattentau
Nov 26, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Deepa RaiVladimir P Badovinac
Nov 2, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Daniel S McDermott, Steven M Varga
Jan 6, 2012·The New England Journal of Medicine·Robert B BelsheUNKNOWN Herpevac Trial for Women
Aug 19, 2016·JCI Insight·Christopher D PetroBetsy C Herold

❮ Previous
Next ❯

Citations

Jul 24, 2021·Expert Review of Vaccines·Vindya Nilakshi WijesingheSunil Kumar Lal

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
FACS
ELISA

Software Mentioned

GraphPad
GraphPad Prism

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.